U.S. Markets open in 6 hrs 27 mins

AVROBIO, Inc. (AVRO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
14.04-0.89 (-5.96%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close14.93
Open14.98
Bid0.00 x 800
Ask0.00 x 1400
Day's Range14.01 - 14.98
52 Week Range9.76 - 29.32
Volume190,030
Avg. Volume329,688
Market Cap581.971M
Beta (5Y Monthly)1.41
PE Ratio (TTM)N/A
EPS (TTM)-3.31
Earnings DateMar 15, 2021 - Mar 19, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.71
  • AVROBIO Announces the Appointment of Diana M. Escolar, M.D. as Chief Medical Officer
    Business Wire

    AVROBIO Announces the Appointment of Diana M. Escolar, M.D. as Chief Medical Officer

    AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Diana M. Escolar, M.D., FAAN, as chief medical officer. Dr. Escolar brings deep expertise across rare diseases, with a focus on lysosomal and neurogenetic disorders. She has been heavily involved in guiding the development of new therapies for rare diseases, including Pompe disease.

  • AVROBIO to Present at the ICR Conference 2021
    Business Wire

    AVROBIO to Present at the ICR Conference 2021

    AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present virtually at the ICR Conference 2021 at 11:30 a.m. ET on Thursday, Jan. 14, 2021.

  • AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Business Wire

    AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 85,250 shares of the company’s common stock to three new employees as inducement awards under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).